A new research study from the University of Exeter is investigating whether individuals living with acquired brain injuries (ABI), use social camouflaging strategies, and how these behaviours may relate to mental health outcomes. Led by MSc student Faye Brookes under the supervision of Associate Professor Anna Adlam, the project aims to explore an emerging area…
Category: Research
Bringing together international leaders of Parkinson’s platform trials
Stakeholders involved in the setup and running of Parkinson’s platform trials met recently for the second annual International PD-Platform Meeting, leading to the launch of the Global Alliance for Parkinson’s Platforms (GAPP). Representatives from the UK, France, the US, Norway, and Australia have joined this new international initiative. GAPP has been created through collaboration between…
Link established between Epstein-Barr virus and lupus autoimmunity
Researchers from Stanford Medicine have uncovered compelling evidence that the Epstein‑Barr virus (EBV), present in over 95% of adults worldwide, plays a direct mechanistic role in the development of Systemic Lupus Erythematosus (SLE). The study found that in healthy adults, fewer than one in 10,000 B cells carry latent EBV. In contrast, among those with…
UCL Faculty of Brain Sciences researchers awarded UKRI Future Leaders Fellowships
Congratulations to Angelika Zarkali (ACNR’s Conference News Editor), and Mathieu Bourdenx, who have both been awarded UK Research and Innovation Future Leaders Fellowships! Angelika Zarkali, Senior Research Fellow and Honorary Consultant Neurologist at UCL Dementia Research Centre, Queen Square Institute of Neurology, has been awarded a fellowship worth £2.3 million to explore new treatment approaches…
Pyrimidine Nucleos(t)ide Therapy Shows 95% Reduction in Risk of Death in TK2 Deficiency
Results published in Neurology have highlighted a 95% reduction in the risk of death among patients treated with pyrimidine nucleoside and/or nucleotide therapy for thymidine kinase 2 deficiency (TK2d), a rare mitochondrial disorder. The findings, from a multicentre retrospective chart review, represent the first published data exploring the safety and efficacy of this investigational therapy…
Maura Malpetti awarded European Young Researcher Award 2025
Congratulations to Dr Maura Malpetti (UK DRI at Cambridge), who has won the 2025 European Young Researcher Award from the Fondation Recherche Alzheimer in France. The foundation funds the advancement of research in Alzheimer’s disease and related syndromes in France and beyond. The award supports and encourages an individual European researcher with exceptionally promising work. Maura’s research focuses on in vivo…
Immediate motor gains in tremor-dominant Parkinson’s disease
MR-guided ultrasound targets PTT circuit A new study in the European Journal of Neurology highlights the immediate therapeutic impact of stepwise dual-target MR-guided focused ultrasound (dtMRgFUS) in treating tremor-dominant Parkinson’s disease. This approach targets both the ventral intermediate nucleus (VIM) and the pallidothalamic tract (PTT) in a single session. Twenty patients (mean age 69.3 ± 8.9 years)…
Four-year Clarity-AD data shows Leqembi slows clinical decline
New 48-month findings from the Clarity-AD (NCT03887455) open-label extension (OLE) study, presented at the 2025 Alzheimer’s Association International Conference (AAIC), indicate that individuals with early Alzheimer’s disease (AD) who received continuous treatment with Leqembi experienced slower clinical progression. Notably, those with low tau levels showed sustained improvements in cognition and daily functioning when compared with…
Metabolic syndrome increases risk of Parkinson’s disease
Having a larger waistline, high blood pressure and other risk factors that make up metabolic syndrome is associated with an increased risk of Parkinson’s disease, according to a study published on August 20, 2025, in Neurology®, the medical journal of the American Academy of Neurology. The study does not prove that metabolic syndrome causes Parkinson’s disease; it…
AQNEURSA® gains CHMP backing for Niemann-Pick type C
July 30 2025: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending AQNEURSA® (levacetylleucine) for approval in the EU for the treatment of Niemann-Pick disease type C (NPC). This recommendation positions AQNEURSA as a potential first-line therapy for a disease with limited treatment options…
